Developer docs
API playgroundTry for free, no card

Search company profiles

Melt Pharmaceuticals

Full company profile

uuid00008cc

Namestring
Melt Pharmaceuticals
Legal namestring
Melt Pharmaceuticals, Inc.
Websiteurl
meltpharma.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Melt Pharmaceuticals is a privately held, clinical-stage pharmaceutical company founded in 2019 and based in Brentwood, Tennessee, focused on developing non-opioid, non-intravenous procedural sedation and analgesia therapies for short-term medical procedures. The company's core product, MELT-300, is a proprietary sublingual sedation formulation designed to deliver procedural sedation without opioid exposure or the logistical and infection risks associated with IV administration, targeting hospitals, ambulatory surgery centers, and clinics where opioid avoidance is a priority.

Melt operated with a lean team of 1–10 employees and raised approximately $47.8M cumulatively through SEC Form D exempt securities offerings (with $42.3M sold as of April 2024) to advance MELT-300 and other non-opioid sedation candidates toward FDA approval, targeted for 2028. Harrow, Inc. (NASDAQ:HROW) acquired Melt on November 18, 2025, through its subsidiary Harrow IP LLC, recording $8.5M in acquired in-process research and development expense and integrating MELT-300 into Harrow's portfolio to expand into the needle-free procedural sedation segment (a market projected at $29.91B by 2030 at a 9.7% CAGR).

Commercially, Melt was pre-revenue at acquisition: no products were approved or sold, no marketing or distribution infrastructure was disclosed, and revenue was expected to be generated through future pharmaceutical product sales contingent on regulatory clearance. As a wholly-owned subsidiary of Harrow, Melt's standalone commercial metrics are now subsumed into Harrow's broader ophthalmic-focused pharmaceutical operations.

Short descriptiontext

Melt Pharmaceuticals is a clinical-stage pharmaceutical company developing non-opioid, non-IV sublingual sedation therapies for short-term medical procedures, with MELT-300 as its lead asset. Acquired by Harrow, Inc. in November 2025 to expand into needle-free procedural sedation.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBrentwood, United States
HQ citystring
Brentwood
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
procedural sedation therapy, sublingual sedation drugs, non-opioid analgesics, needle-free sedation, clinical-stage pharmaceuticals
Industry2 codes
PRIMARYHLAIAGAG
Nuclear Medicine Imaging Agents & Kits (Cold Kits/Precursors)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHSALAFAH
Hot/Cold Therapy Services (Cryotherapy/Ice Baths)
NAICS code2 codes
  • Cookie, Cracker, and Pasta Manufacturing31182
  • Cookie and Cracker Manufacturing311821
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Surgical & Medical Instruments & Apparatus3841
Product category
Procedural Sedation Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical product sales
TypeOne Time License
Description

Melt Pharmaceuticals develops pharmaceutical products for procedural sedation. Revenue will be generated through product sales following regulatory approval. As of the November 2025 acquisition, products were in clinical development with planned regulatory submission by 2028.

globenewswire.com
Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1MELT-300
Description

Non-opioid, non-IV procedural sedation therapy product under development by Melt Pharmaceuticals, targeting transformation of procedural sedation and reduction of opioid exposure.

globenewswire.com
Core offering1 text field

Melt Pharmaceuticals develops non-opioid, non-IV sublingual sedation therapies intended for procedural sedation and analgesia during short-term medical procedures. Its lead candidate, MELT-300, is a proprietary sublingual formulation designed to deliver sedation without intravenous access or opioid exposure. Following the November 2025 acquisition by Harrow, Inc., Melt's products remain in clinical development with regulatory submission targeted for 2028.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Melt Pharmaceuticals is a clinical-stage pharmaceutical company specializing in non-opioid, non-IV sedation therapies. The company's primary product is MELT-300, a sublingual sedation therapy designed to provide procedural sedation without the need for opioids or intravenous administration. The company was acquired by Harrow IP LLC in November 2025 to expand into needle-free procedural sedation. Clinical development and regulatory approval for MELT-300 are targeted for 2028.

Product and service1 record
1MELT-300
CategoryProcedural Sedation Pharmaceuticals
Description

A non-opioid, non-IV sublingual procedural sedation therapy designed to transform procedural sedation and reduce opioid exposure in medical settings such as hospitals, ambulatory surgery centers, and clinics performing short-term procedures.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-18
Description

Harrow, Inc. acquired Melt Pharmaceuticals on November 18, 2025, through its subsidiary Harrow IP LLC. The acquisition was made to expand Harrow into needle-free procedural sedation. Melt's non-opioid, non-IV sedation therapies, including MELT-300, were integrated into Harrow's portfolio with plans for further clinical development and regulatory approval by 2028.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Developer of sublingual sufentanil (DSUVIA) for procedural pain management in medically supervised settings. Highly comparable to Melt given its focus on sublingual drug delivery for acute procedural use cases in hospitals and surgical centers.

TypeDirect peer
Description

Markets Byfavo (remimazolam), an injectable procedural sedation agent, along with other specialty injectable products. Directly comparable to Melt as a player in the procedural sedation pharmaceutical market with novel mechanism products.

TypeDirect peer
Description

Specialty pharmaceutical company focused on procedural sedation and supportive care, including licensing rights to Byfavo in the U.S. Directly comparable to Melt given its concentrated focus on the procedural sedation therapeutic area and hospital/ASC channel.

TypeDirect peer
Description

Developer of EXPAREL, a long-acting non-opioid local anesthetic for postsurgical pain control. Comparable to Melt as a non-opioid specialty pharmaceutical company targeting the surgical and procedural care setting with differentiated delivery technology.

TypeDirect peer
Description

Developer of ZYNRELEF, a non-opioid extended-release local anesthetic for postoperative pain, and other specialty pharmaceutical products. Comparable to Melt as a non-opioid procedural and postsurgical pain management company with hospital channel focus.

TypeEmerging player
Description

Developed OLINVYK, an opioid-sparing IV analgesic for acute pain in hospital settings. Comparable as a smaller specialty pharma focused on opioid-alternative therapies for procedural and acute care use cases.

TypeBroad incumbent
Description

Major pharmaceutical company that markets widely used procedural sedation agents including midazolam and other benzodiazepines. Comparable as the incumbent standard-of-care provider in procedural sedation against which Melt's novel non-opioid alternative will compete.

TypeOthers
Description

Parent company of Melt following the November 2025 acquisition, and a publicly traded specialty ophthalmic pharmaceutical company. Included as the strategic acquirer and now operator of Melt's clinical pipeline, providing commercialization infrastructure.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Melt Pharmaceuticals

Procedural Sedation Pharmaceuticalsmeltpharma.com

Melt Pharmaceuticals is a clinical-stage pharmaceutical company developing non-opioid, non-IV sublingual sedation therapies for short-term medical procedures, with MELT-300 as its lead asset. Acquired by Harrow, Inc. in November 2025 to expand into needle-free procedural sedation.

What Melt Pharmaceuticals does

Melt Pharmaceuticals is a privately held, clinical-stage pharmaceutical company founded in 2019 and based in Brentwood, Tennessee, focused on developing non-opioid, non-intravenous procedural sedation and analgesia therapies for short-term medical procedures. The company's core product, MELT-300, is a proprietary sublingual sedation formulation designed to deliver procedural sedation without opioid exposure or the logistical and infection risks associated with IV administration, targeting hospitals, ambulatory surgery centers, and clinics where opioid avoidance is a priority.

Melt operated with a lean team of 1–10 employees and raised approximately $47.8M cumulatively through SEC Form D exempt securities offerings (with $42.3M sold as of April 2024) to advance MELT-300 and other non-opioid sedation candidates toward FDA approval, targeted for 2028. Harrow, Inc. (NASDAQ:HROW) acquired Melt on November 18, 2025, through its subsidiary Harrow IP LLC, recording $8.5M in acquired in-process research and development expense and integrating MELT-300 into Harrow's portfolio to expand into the needle-free procedural sedation segment (a market projected at $29.91B by 2030 at a 9.7% CAGR).

Commercially, Melt was pre-revenue at acquisition: no products were approved or sold, no marketing or distribution infrastructure was disclosed, and revenue was expected to be generated through future pharmaceutical product sales contingent on regulatory clearance. As a wholly-owned subsidiary of Harrow, Melt's standalone commercial metrics are now subsumed into Harrow's broader ophthalmic-focused pharmaceutical operations.

Melt Pharmaceuticals firmographics

Firmographics
Name
Melt Pharmaceuticals
Legal name
Melt Pharmaceuticals, Inc.
Website
https://meltpharma.com
Company type
Private
Founded year
2019
Operating status
Acquired
Headcount range
1–10 employees
Short description
Melt Pharmaceuticals is a clinical-stage pharmaceutical company developing non-opioid, non-IV sublingual sedation therapies for short-term medical procedures, with MELT-300 as its lead asset. Acquired by Harrow, Inc. in November 2025 to expand into needle-free procedural sedation.
Ownership category
akta.pro rank

Melt Pharmaceuticals industry classification

Industry
Product category
Procedural Sedation Pharmaceuticals
NAICS
Cookie, Cracker, and Pasta Manufacturing (31182), Cookie and Cracker Manufacturing (311821)
SIC
Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAIAGAG
Nuclear Medicine Imaging Agents & Kits (Cold Kits/Precursors)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHSALAFAH
Hot/Cold Therapy Services (Cryotherapy/Ice Baths)

Keywords

  • Procedural sedation therapy
  • Sublingual sedation drugs
  • Non-opioid analgesics
  • Needle-free sedation
  • Clinical-stage pharmaceuticals

Where Melt Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Brentwood
HQ country
United States
HQ region
North America

Markets served

Melt Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Pharmaceutical product sales: Melt Pharmaceuticals develops pharmaceutical products for procedural sedation. Revenue will be generated through product sales following regulatory approval. As of the November 2025 acquisition, products were in clinical development with planned regulatory submission by 2028.

Go-to-market motion1 record

Melt Pharmaceuticals product offering

Product offering

Core offering

Melt Pharmaceuticals develops non-opioid, non-IV sublingual sedation therapies intended for procedural sedation and analgesia during short-term medical procedures. Its lead candidate, MELT-300, is a proprietary sublingual formulation designed to deliver sedation without intravenous access or opioid exposure. Following the November 2025 acquisition by Harrow, Inc., Melt's products remain in clinical development with regulatory submission targeted for 2028.

Product overview

Melt Pharmaceuticals is a clinical-stage pharmaceutical company specializing in non-opioid, non-IV sedation therapies. The company's primary product is MELT-300, a sublingual sedation therapy designed to provide procedural sedation without the need for opioids or intravenous administration. The company was acquired by Harrow IP LLC in November 2025 to expand into needle-free procedural sedation. Clinical development and regulatory approval for MELT-300 are targeted for 2028.

Differentiator

Problem solved

Functional benefit

Brands

  • MELT-300: Non-opioid, non-IV procedural sedation therapy product under development by Melt Pharmaceuticals, targeting transformation of procedural sedation and reduction of opioid exposure.

Products and services

  • MELT-300 A non-opioid, non-IV sublingual procedural sedation therapy designed to transform procedural sedation and reduce opioid exposure in medical settings such as hospitals, ambulatory surgery centers, and clinics performing short-term procedures.

Companies that use Melt Pharmaceuticals

Customer profile

Segments1 record

Ideal customer profiles1 record

Melt Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Melt Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Harrow, Inc. (Harrow IP LLC)coreStrategic or Co-development Partner · 18 November 2025Harrow, Inc. acquired Melt Pharmaceuticals on November 18, 2025, through its subsidiary Harrow IP LLC. The acquisition was made to expand Harrow into needle-free procedural sedation. Melt's non-opioid, non-IV sedation therapies, including MELT-300, were integrated into Harrow's portfolio with plans for further clinical development and regulatory approval by 2028.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Melt Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • AcelRx Pharmaceuticals: Developer of sublingual sufentanil (DSUVIA) for procedural pain management in medically supervised settings. Highly comparable to Melt given its focus on sublingual drug delivery for acute procedural use cases in hospitals and surgical centers.
  • Eagle Pharmaceuticals: Markets Byfavo (remimazolam), an injectable procedural sedation agent, along with other specialty injectable products. Directly comparable to Melt as a player in the procedural sedation pharmaceutical market with novel mechanism products.
  • Acacia Pharma Group: Specialty pharmaceutical company focused on procedural sedation and supportive care, including licensing rights to Byfavo in the U.S. Directly comparable to Melt given its concentrated focus on the procedural sedation therapeutic area and hospital/ASC channel.
  • Pacira BioSciences: Developer of EXPAREL, a long-acting non-opioid local anesthetic for postsurgical pain control. Comparable to Melt as a non-opioid specialty pharmaceutical company targeting the surgical and procedural care setting with differentiated delivery technology.
  • Heron Therapeutics: Developer of ZYNRELEF, a non-opioid extended-release local anesthetic for postoperative pain, and other specialty pharmaceutical products. Comparable to Melt as a non-opioid procedural and postsurgical pain management company with hospital channel focus.

Emerging players

  • Trevena Inc. Developed OLINVYK, an opioid-sparing IV analgesic for acute pain in hospital settings. Comparable as a smaller specialty pharma focused on opioid-alternative therapies for procedural and acute care use cases.

Broad incumbents

  • Pfizer: Major pharmaceutical company that markets widely used procedural sedation agents including midazolam and other benzodiazepines. Comparable as the incumbent standard-of-care provider in procedural sedation against which Melt's novel non-opioid alternative will compete.

Others

  • Harrow, Inc. Parent company of Melt following the November 2025 acquisition, and a publicly traded specialty ophthalmic pharmaceutical company. Included as the strategic acquirer and now operator of Melt's clinical pipeline, providing commercialization infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key highlights6 records

Customer concentration

Melt Pharmaceuticals social profiles

Digital presence

Melt Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Melt Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles2 records

Melt Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Melt Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Melt Pharmaceuticals

What does Melt Pharmaceuticals do?

Melt Pharmaceuticals develops non-opioid, non-IV sublingual sedation therapies intended for procedural sedation and analgesia during short-term medical procedures. Its lead candidate, MELT-300, is a proprietary sublingual formulation designed to deliver sedation without intravenous access or opioid exposure. Following the November 2025 acquisition by Harrow, Inc., Melt's products remain in clinical development with regulatory submission targeted for 2028.

Is Melt Pharmaceuticals a public or private company?

Melt Pharmaceuticals is a private company. It is classified as corporate owned and is currently acquired.

When was Melt Pharmaceuticals founded?

Melt Pharmaceuticals was founded in 2019. It employs 1 to 10 people.

Where is Melt Pharmaceuticals based?

Melt Pharmaceuticals is headquartered in Brentwood, United States, in the North America region.

How does Melt Pharmaceuticals make money?

One revenue line is on record: pharmaceutical product sales.

Who are Melt Pharmaceuticals's main competitors?

Direct peers on record are AcelRx Pharmaceuticals, Eagle Pharmaceuticals, Acacia Pharma Group, Pacira BioSciences and Heron Therapeutics. Trevena Inc. is listed as an emerging player. Pfizer is listed as a broad incumbent. Harrow, Inc. is listed as an others.

Does Melt Pharmaceuticals have an API?

No public API is recorded for Melt Pharmaceuticals.

What industry is Melt Pharmaceuticals in?

Melt Pharmaceuticals's product category is Procedural Sedation Pharmaceuticals. Its primary akta.pro industry code is HLAIAGAG, Nuclear Medicine Imaging Agents & Kits (Cold Kits/Precursors), with a secondary code of HSALAFAH, Hot/Cold Therapy Services (Cryotherapy/Ice Baths). Its NAICS code is 31182 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comEmerging Sub-Segments Transforming the Needle-Free Drug Delivery Devices Market LandscapeThe needle-free drug delivery devices market is projected to reach $29.91 billion by 2030, growing at a compound annual growth rate of 9.7%, driven by rising chronic disease prevalence, demand for self-administration therapies, and advances in microneedle and transdermal systems. In November 2025, Harrow IP LLC acquired Melt Pharmaceuticals to expand into needle-free procedural sedation, integrating Melt's non-opioid sublingual sedation therapies. In May 2025, Imperative Care Inc. launched a dual-catheter stroke aspiration system designed to remove blood clots in acute ischemic stroke care.BenzingaThese Analysts Revise Their Forecasts On Harrow Following Q4 Results - Harrow (NASDAQ:HROW)Harrow Inc. posted mixed fourth-quarter results, beating sales estimates at $89.09 million versus the $88.45 million consensus but missing earnings per share at 17 cents against a 38-cent consensus estimate. The company recorded $8.5 million in acquired in-process research and development expenses related to its acquisition of Melt Pharmaceuticals and issued fiscal 2026 sales guidance of $350 million to $365 million, below the $386.26 million consensus. Following the announcement, HC Wainwright analyst Yi Chen raised the price target to $70 (maintaining Buy) while Cantor Fitzgerald analyst Steve Seedhouse lowered the target to $91 (maintaining Overweight).BenzingaWhy Is Eye-Disease-Focused Harrow Stock Falling Today? (UPDATED) - Harrow (NASDAQ:HROW)Harrow Inc. (NASDAQ:HROW) reported fourth quarter earnings of 17 cents per share, missing the consensus estimate of 38 cents, while sales of $89.09 million beat expectations of $88.45 million; shares dropped 25.04% to $40.17 during Tuesday's premarket session. The company provided fiscal 2026 sales guidance of $350 million to $365 million, below the consensus estimate of $386.26 million, and recorded $8.5 million in acquired in-process R&D expenses related to its acquisition of Melt Pharmaceuticals. CEO Mark Baum expressed confidence in future performance, highlighting multiple growth drivers and a goal of over $250 million in quarterly revenue by the end of 2027.GlobeNewswireHarrow Announces Closing of Acquisition of Melt PharmaceuticalsHarrow has completed its acquisition of Melt Pharmaceuticals, a clinical-stage pharmaceutical company developing non-opioid, non-IV sedation therapies, marking a strategic expansion of Harrow's portfolio into the procedural sedation market. The lead candidate, MELT-300, a sublingual midazolam and ketamine formulation, demonstrated statistical superiority in Phase 3 trials and is on track for an NDA submission in H1 2027 with potential FDA approval in H1 2028. Harrow plans to leverage its existing commercial infrastructure and the network of over 800 ophthalmic institutions currently using its compounded MKO Melt product to drive adoption.GlobeNewswireHarrow Announces Third Quarter 2025 Financial ResultsHarrow, Inc. reported third quarter 2025 financial results on November 10, 2025, with total revenues of $71.6 million, a 45% increase from $49.3 million in the prior-year period, and returned to GAAP profitability with net income of $1.0 million compared to a loss of $4.2 million in Q3 2024. Adjusted EBITDA grew to $22.7 million, and the company announced strategic initiatives including a coverage expansion for VEVYE with major national payers, a partnership with Alto Pharmacy Powered by Fuze Health, and an agreement to acquire Melt Pharmaceuticals for its non-opioid sedation therapy pipeline.BenzingaHarrow Buys Melt Pharma For Needle-Free Sedation - Harrow (NASDAQ:HROW)Harrow, Inc. (NASDAQ: HROW) has agreed to acquire Melt Pharmaceuticals, Inc., a clinical-stage company developing non-opioid, non-IV sedation therapies, for undisclosed terms in a deal contingent on customary closing conditions. Melt's leading product MELT-300 is a patented sublingual tablet combining midazolam and ketamine designed for needle-free procedural sedation, with Harrow planning to submit a New Drug Application to the FDA in 2027 targeting a U.S. launch in 2028. The therapy builds on over ten years of physician experience with Harrow's existing MKO Melt sublingual sedation used in over 500,000 cataract surgeries, positioning the company to enter the multi-billion-dollar U.S. procedural sedation market and reduce opioid dependence in outpatient care.Nashville PostHarrow to purchase Melt PharmaceuticalsHarrow Inc. announced an agreement to acquire Melt Pharmaceuticals, a Nashville-based eye care pharmaceutical company. Financial terms of the deal were not disclosed. The acquisition is expected to be completed in the fourth quarter.PentaVisionHarrow Enters Agreement to Acquire Melt PharmaceuticalsHarrow has entered into an agreement to acquire Melt Pharmaceuticals, a clinical-stage company developing sublingual non-opioid sedation therapies, subject to Melt stockholder approval. MELT-300, Melt's lead candidate combining midazolam and ketamine, demonstrated statistical superiority over sublingual midazolam and placebo in the Phase 3 LOUISE trial under FDA special protocol assessment, supporting a planned new drug application filing in 2027 with a potential US launch in 2028. Harrow expects MELT-300 to address the over 4 million annual US cataract surgeries and expand into other procedural sedation markets, eventually replacing its existing compounded MKO Melt product.HarrowHarrow to Acquire Melt PharmaceuticalsHarrow (Nasdaq: HROW) has announced an agreement to acquire Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing non-opioid, non-IV sedation therapies for medical procedures. Melt's lead investigational therapy MELT-300 demonstrated statistical superiority over sublingual midazolam alone (P=0.009) and placebo (P<0.0001) in the pivotal Phase 3 LOUISE study conducted under an SPA agreement with the FDA. Harrow plans to submit a New Drug Application for MELT-300 in 2027 with a potential U.S. commercial launch in 2028, representing entry into the multi-billion-dollar U.S. procedural sedation market.